Carregant...
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + ME...
Guardat en:
| Publicat a: | Cancer Discov |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007378/ https://ncbi.nlm.nih.gov/pubmed/31796433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0672 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|